# An erectile disfunction drug could be the next Alzheimer’s treatment

- URL: https://talkfuse.com/story/an-erectile-disfunction-drug-could-be-the-next-alzheimers-treatment/
- Published: 2026-11-18T15:25:27+00:00
- Updated: 2026-11-18T16:42:22+00:00
- Original publisher: New York Post (publisher lean: Right)
- Original article: https://nypost.com/2026/11/18/health/an-erectile-disfunction-drug-could-treat-alzheimers/
- Topics: Americas, Asia, Health, Medicine, World

## Key points

- AR1001 showed a 31% reduction in decline for one trial subgroup.
- The overall trial result was not statistically significant.
- Its maker plans to seek US approval in 2027.

## Summary

A phase 3 trial found that AR1001, a daily pill made with a lower dose of the erectile dysfunction drug mirodenafil, may slow cognitive decline in some people with early Alzheimer’s. The result could point to a new treatment option, but the benefit was limited to a subgroup and the drug is not approved in the US.

After one year, participants not taking standard Alzheimer’s medicines had 31% less clinical decline with AR1001 than those given a placebo. Across all 1,535 trial participants, including those taking other Alzheimer’s drugs, the difference was not statistically significant; improvements on memory and daily-function tests were also not consistently significant. AriBio plans to apply for FDA approval in 2027. If approved, AR1001 would be a daily pill alongside the two existing drugs that can slow progression, donanemab and lecanemab, which are given by infusion.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.
